In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

Polymyxins are well-established antibiotics that have recently regained significant interest
as a consequence of the increasing incidence of infections due to multidrug-resistant Gram …

Background The β-lactamase inhibitor relebactam can restore imipenem activity against
imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam …

Purpose Colistin is an antibiotic that was introduced many years ago and was withdrawn
because of its nephrotoxicity. Nowadays, reemergence of this antibiotic for multi-drug …

Colistin is a polymyxin antibiotic that was discovered in the late 1940s for the treatment of
gram‐negative infections. After several years of clinical use, its popularity diminished …

Background Nephrotoxicity and neurotoxicity are commonly associated with polymyxin
treatment; however, the emergence of multidrug-resistant Gram-negative bacteria with …

Colistin has been re-introduced into clinical practice for the treatment of carbapenem-
resistant Gram-negative bacteria. Studies in the last decade attempted to reconstruct the …

Colistin is a complex polypeptide antibiotic composed mainly of colistin A and B. It was
abandoned from clinical use in the 1970s because of significant renal and, to a lesser …

Background. Gram-negative bacteria susceptible only to colistin (COS) are emerging causes
of severe nosocomial infections, reviving interest in the use of colistin. However, consensus …

Abstract (See the Editorial Commentary by Falagas and Rafailidis, on pages 681–3.)
Background. Experience with intravenous and aerosolized forms of colistin for the treatment …